Integrated in Silico Docking and MOMA Simulation Methods Reveal Rottlerin as a Potent Janus kinase 2 (JAK2) Inhibitor

Authors:

Abstract
Janus kinase 2 (JAK2) is a prospective drug target for myeloproliferative neoplasms, mainly polycythemia Vera, essential thrombocythemia and primary myelofibrosis disorders. JAK2 abnormalities are mainly identified in myeloid neoplasms.